Literature DB >> 18978305

Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay.

Debasis Patnaik1, Marcie A Glicksman, Gregory D Cuny, Ross L Stein, Jonathan M G Higgins.   

Abstract

Haspin/Gsg2 is a kinase that phosphorylates histone H3 at Thr-3 (H3T3ph) during mitosis. Its depletion by RNA interference results in failure of chromosome alignment and a block in mitosis. Haspin, therefore, is a novel target for development of antimitotic agents. We report the development of a high-throughput time-resolved fluorescence resonance energy transfer (TR-FRET) kinase assay for haspin. Histone H3 peptide was used as a substrate, and a europium-labeled H3T3ph phosphospecific monoclonal antibody was used to detect phosphorylation. A library of 137632 small molecules was screened at K(m) concentrations of ATP and peptide to allow identification of diverse inhibitor types. Reconfirmation of hits and IC( 50) determinations were carried out with the TR-FRET assay and by a radiometric assay using recombinant histone H3 as the substrate. A preliminary assessment of specificity was made by testing inhibition of 2 unrelated kinases. EC( 50) values in cells were determined using a cell-based ELISA of H3T3ph. Five compounds were selected as leads based on potency and chemical structure considerations. These leads form the basis for the development of specific inhibitors of haspin that will have clear utility in basic research and possible use as starting points for development of antimitotic anticancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978305      PMCID: PMC2615828          DOI: 10.1177/1087057108326081

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  20 in total

1.  HTRF(R) Technology.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

3.  LANCEtrade mark: Homogeneous Assay Platform for HTS.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 4.  Aurora-kinase inhibitors as anticancer agents.

Authors:  Nicholas Keen; Stephen Taylor
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

5.  Crystal structure of the nucleosome core particle at 2.8 A resolution.

Authors:  K Luger; A W Mäder; R K Richmond; D F Sargent; T J Richmond
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

Review 6.  Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer.

Authors:  G Mathis
Journal:  Clin Chem       Date:  1995-09       Impact factor: 8.327

7.  Haspin: a mitotic histone kinase required for metaphase chromosome alignment.

Authors:  Jun Dai; Jonathan M G Higgins
Journal:  Cell Cycle       Date:  2005-05-04       Impact factor: 4.534

Review 8.  Structure, function and evolution of haspin and haspin-related proteins, a distinctive group of eukaryotic protein kinases.

Authors:  J M G Higgins
Journal:  Cell Mol Life Sci       Date:  2003-03       Impact factor: 9.261

Review 9.  Targeting polo-like kinase 1 for cancer therapy.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

Review 10.  Polo and Aurora kinases: lessons derived from chemical biology.

Authors:  Stephen Taylor; Jan-Michael Peters
Journal:  Curr Opin Cell Biol       Date:  2008-01-30       Impact factor: 8.382

View more
  19 in total

1.  Towards Gram-positive antivirulence drugs: new inhibitors of Streptococcus agalactiae Stk1.

Authors:  Mayalen Oxoby; François Moreau; Lionel Durant; Alexis Denis; Jean-Marie Genevard; Vanida Vongsouthi; Sonia Escaich; Vincent Gerusz
Journal:  Bioorg Med Chem Lett       Date:  2010-06-15       Impact factor: 2.823

2.  Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization.

Authors:  Fabrizio Villa; Paola Capasso; Marcello Tortorici; Federico Forneris; Ario de Marco; Andrea Mattevi; Andrea Musacchio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

Review 3.  Haspin: a newly discovered regulator of mitotic chromosome behavior.

Authors:  Jonathan M G Higgins
Journal:  Chromosoma       Date:  2009-12-08       Impact factor: 4.316

4.  Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors.

Authors:  Gregory D Cuny; Maxime Robin; Natalia P Ulyanova; Debasis Patnaik; Valerie Pique; Gilles Casano; Ji-Feng Liu; Xiangjie Lin; Jun Xian; Marcie A Glicksman; Ross L Stein; Jonathan M G Higgins
Journal:  Bioorg Med Chem Lett       Date:  2010-06-15       Impact factor: 2.823

5.  Perturbation of mitosis through inhibition of histone acetyltransferases: the key to ochratoxin a toxicity and carcinogenicity?

Authors:  Kristin Czakai; Katja Müller; Pasquale Mosesso; Gaetano Pepe; Markus Schulze; Antje Gohla; Debasis Patnaik; Wolfgang Dekant; Jonathan M G Higgins; Angela Mally
Journal:  Toxicol Sci       Date:  2011-05-06       Impact factor: 4.849

6.  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.

Authors:  Gregory D Cuny; Natalia P Ulyanova; Debasis Patnaik; Ji-Feng Liu; Xiangjie Lin; Ken Auerbach; Soumya S Ray; Jun Xian; Marcie A Glicksman; Ross L Stein; Jonathan M G Higgins
Journal:  Bioorg Med Chem Lett       Date:  2012-01-28       Impact factor: 2.823

7.  Co-crystal structures of the protein kinase haspin with bisubstrate inhibitors.

Authors:  Darja Lavogina; Katrin Kestav; Apirat Chaikuad; Christina Heroven; Stefan Knapp; Asko Uri
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-04-22       Impact factor: 1.056

8.  3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties.

Authors:  Clement Opoku-Temeng; Neetu Dayal; Moloud Aflaki Sooreshjani; Herman O Sintim
Journal:  Bioorg Chem       Date:  2018-04-17       Impact factor: 5.275

9.  Structure and functional characterization of the atypical human kinase haspin.

Authors:  Jeyanthy Eswaran; Debasis Patnaik; Panagis Filippakopoulos; Fangwei Wang; Ross L Stein; James W Murray; Jonathan M G Higgins; Stefan Knapp
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

10.  Haspin inhibition delays cell cycle progression through interphase in cancer cells.

Authors:  Peiling Wang; Xiangmei Hua; Yuge Han Bryner; Sijing Liu; Christopher B Gitter; Jun Dai
Journal:  J Cell Physiol       Date:  2019-10-17       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.